IceCure's ProSense Cryoablation Featured In Six Global Studies At 2024 EUSOBI Conference
Portfolio Pulse from Benzinga Newsdesk
IceCure's ProSense Cryoablation technology was highlighted in six global studies at the 2024 EUSOBI Conference. The ICE3 trial results, presented by Dr. Kenneth Tomkovich, won the EUSOBI Abstract Award. The THERMAC trial showed a 94% complete ablation rate for breast cancer using cryoablation. IceCure also conducted hands-on demonstrations at the event.
October 07, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure's ProSense Cryoablation technology received significant recognition at the 2024 EUSOBI Conference, with the ICE3 trial winning an award and the THERMAC trial showing promising results for breast cancer treatment.
The recognition of IceCure's technology at a major conference and the positive trial results are likely to boost investor confidence and interest in the company's stock, potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100